AbbVie Inc. Issuance/Purchase of Shares

Issuance/Purchase of Shares of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Issuance/Purchase of Shares growth rates and interactive chart.


Highlights and Quick Summary

  • Issuance/Purchase of Shares for the quarter ending March 30, 2021 was $-716 Million (a 265.31% increase compared to previous quarter)
  • Year-over-year quarterly Issuance/Purchase of Shares decreased by -1656.52%
  • Annual Issuance/Purchase of Shares for 2020 was $-769 Million (a 23.83% increase from previous year)
  • Annual Issuance/Purchase of Shares for 2019 was $-621 Million (a -94.8% decrease from previous year)
  • Annual Issuance/Purchase of Shares for 2018 was $-11.9 Billion (a 932.96% increase from previous year)
  • Twelve month Issuance/Purchase of Shares ending March 30, 2021 was $-854 Million (a 11.05% increase compared to previous quarter)
  • Twelve month trailing Issuance/Purchase of Shares increased by 45.24% year-over-year
Trailing Issuance/Purchase of Shares for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$-854 Million $-769 Million $-573 Million $-588 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Issuance/Purchase of Shares of AbbVie Inc.

Most recent Issuance/Purchase of Sharesof ABBV including historical data for past 10 years.

Interactive Chart of Issuance/Purchase of Shares of AbbVie Inc.

AbbVie Inc. Issuance/Purchase of Shares for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-716.0
2020 $-196.0 $12.0 $46.0 $-631.0 $-769.0
2019 $0.0 $-3.0 $-2.0 $-616.0 $-621.0
2018 $-2,051.0 $-1,007.0 $-7,514.0 $-1,369.0 $-11,941.0
2017 $-465.0 $60.0 $59.0 $-810.0 $-1,156.0
2016 $-1,752.0 $35.0 $-3,716.0 $-332.0 $-5,765.0
2015 $-1,212.0 $-976.0 $-4,948.0 $-295.0 $-7,431.0
2014 $-245.0 $38.0 $18.0 $-244.0 $-433.0
2013 $-98.0 $56.0 $75.0 $-6.0 $27.0
2011 $0.0
2010 $0.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.